Nanocan Therapeutics Corporation
Adam Shilling possesses extensive experience in regulatory affairs and drug development across several prominent pharmaceutical companies. Currently serving as the Chief Development Officer at Nanocan Therapeutics Corporation since September 2022, Adam leads strategy and execution for regulatory and clinical functions. As the President and Founder of AS Pharma Consulting, LLC since April 2022, Adam provides expert consulting services for drug development. Previous roles include Vice President of Early Development and Regulatory Affairs at Prelude Therapeutics Incorporated and Executive Director of Regulatory Affairs at Incyte Pharmaceuticals, where Adam defined global regulatory strategies and coordinated submissions for numerous programs. Adam's academic background includes a Ph.D. in Toxicology from Oregon State University and a B.S. in Marine Biology from Long Island University, Southampton Campus.
This person is not in any teams
This person is not in any offices
Nanocan Therapeutics Corporation
Nanocan Therapeutics provides medicines and other products intended to patients with certain cancers, respiratory tract infections. The company leverages nanotechnology to create solutions for hard-to-cure indications where current interventions are insufficient. Through the application of nanotechnology to medicine, Nanocan aims to help improvethe quality of life of our patients, increase access to medicine and other treatments, and to reduce global health disparities.